U.S. Markets closed
  • S&P 500

    3,662.45
    +40.82 (+1.13%)
     
  • Dow 30

    29,823.92
    +185.28 (+0.63%)
     
  • Nasdaq

    12,355.11
    +156.37 (+1.28%)
     
  • Russell 2000

    1,836.05
    +16.23 (+0.89%)
     
  • Crude Oil

    44.40
    -0.94 (-2.07%)
     
  • Gold

    1,813.90
    +38.20 (+2.15%)
     
  • Silver

    24.06
    +1.52 (+6.75%)
     
  • EUR/USD

    1.2071
    +0.0137 (+1.1468%)
     
  • 10-Yr Bond

    0.9340
    +0.0900 (+10.66%)
     
  • Vix

    20.77
    +0.20 (+0.97%)
     
  • GBP/USD

    1.3432
    +0.0100 (+0.7535%)
     
  • USD/JPY

    104.3070
    -0.0170 (-0.0163%)
     
  • BTC-USD

    19,150.90
    -248.86 (-1.28%)
     
  • CMC Crypto 200

    375.94
    -3.92 (-1.03%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,787.54
    +353.92 (+1.34%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FENC, BMRN and CACC

·3 min read

NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: February 11, 2020 - August 10, 2020
Lead Plaintiff Deadline: November 2, 2020

The FENC lawsuit alleges that Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in FENC: http://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?id=10430&from=1

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Class Period: February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline: November 24, 2020

BioMarin Pharmaceutical Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BMRN: http://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?id=10430&from=1

Credit Acceptance Corporation (NASDAQ:CACC)
Class Period: November 1, 2019 - August 28, 2020
Lead Plaintiff Deadline: December 1, 2020

The CACC lawsuit alleges Credit Acceptance Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, Defendants positive statements about the Company's business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in CACC: http://www.kleinstocklaw.com/pslra-1/credit-acceptance-corporation-loss-submission-form?id=10430&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899, or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/612008/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FENC-BMRN-and-CACC